-
Je něco špatně v tomto záznamu ?
Different mechanisms of drug resistance in myelodysplastic syndromes and acute myeloid leukemia
Lucia Messingerova, Denisa Imrichova, Martina Coculova, Marian Zelina, Lucia Pavlikova, Helena Kavcova, Mario Seres, Viera Bohacova, Boris Lakatos, Zdena Sulova and Albert Breier
Jazyk angličtina Země Chorvatsko
- MeSH
- akutní myeloidní leukemie terapie MeSH
- chemorezistence MeSH
- léková rezistence MeSH
- lidé MeSH
- myelodysplastické syndromy terapie MeSH
- Check Tag
- lidé MeSH
Myelodysplastic syndromes (MDSs) represent clonal hematopoietic stem cell (HSC) disorders in which genetic and/or epigenetic alteration are involved in the normal function of hematopoietic stem and progenitor cells. This results in the development of blood cytopenias and bone marrow dysplasia. In recent years, therapy with hypomethylating agents (HMAs) in combination with supportive therapies is recommended as frontline treatment for patients with high-risk MDSs according to International Prognostic Scoring System (IPSS HR-MDS). Therapy with HMAs is essential namely for IPSS HR-MDS patients who do not proceed to immediate allogeneic stem cell transplantation (al‐ loSCT). For IPSS LR-MDS (International Prognostic Scoring System, low-risk MDSs) patients, however, supportive therapies and growth factors are the mainstay of treatment. Some patients in this group are treated with immunomodulatory agents derived from thalidomide (lenalidomide) or using immunosuppressive therapy (IST). The therapeu‐ tic decisions can change during the course of the disease based on changes in risk- category and the functional status of patients, in response to prior therapies, changes in patient preferences, and other factors. Resistance to chemotherapy is a serious obstacle to the successful treatment of overall malignancies, including AML and MDS. The failure of therapeutic treatment may be due to the development of multidrug resistance (MDR) phenotype. MDR represents the induction of large-scale defensive mechanisms from which the upregulation of membrane transporters (like P-glycoprotein – P-gp) effluxing chemotherapeutic drugs from tumor cells represents the most observed molecular causality. Other mechanisms of MDR include drug metabolism, alterations in drug-induced apoptosis, epigenetic changes, epithelial-mesenchymal transition, alteration in drug targets structures, and acceleration of DNA repair. The present contribution represents a state-of-the-art review of available knowledge about this issue.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18009521
- 003
- CZ-PrNML
- 005
- 20180403122906.0
- 007
- ta
- 008
- 180329s2016 ci f 000 0|eng||
- 009
- PB
- 024 7_
- $a 10.5772/63483 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a ci
- 100 1_
- $a Messingerová, L. $7 _AN049583 $u Institute of Biochemistry and Microbiology, Faculty of Chemical and Food Technology, Slovak University of Technology, Bratislava, Slovakia; Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences, Bratislava, Slovakia
- 245 10
- $a Different mechanisms of drug resistance in myelodysplastic syndromes and acute myeloid leukemia / $c Lucia Messingerova, Denisa Imrichova, Martina Coculova, Marian Zelina, Lucia Pavlikova, Helena Kavcova, Mario Seres, Viera Bohacova, Boris Lakatos, Zdena Sulova and Albert Breier
- 504 __
- $a Literatura
- 520 9_
- $a Myelodysplastic syndromes (MDSs) represent clonal hematopoietic stem cell (HSC) disorders in which genetic and/or epigenetic alteration are involved in the normal function of hematopoietic stem and progenitor cells. This results in the development of blood cytopenias and bone marrow dysplasia. In recent years, therapy with hypomethylating agents (HMAs) in combination with supportive therapies is recommended as frontline treatment for patients with high-risk MDSs according to International Prognostic Scoring System (IPSS HR-MDS). Therapy with HMAs is essential namely for IPSS HR-MDS patients who do not proceed to immediate allogeneic stem cell transplantation (al‐ loSCT). For IPSS LR-MDS (International Prognostic Scoring System, low-risk MDSs) patients, however, supportive therapies and growth factors are the mainstay of treatment. Some patients in this group are treated with immunomodulatory agents derived from thalidomide (lenalidomide) or using immunosuppressive therapy (IST). The therapeu‐ tic decisions can change during the course of the disease based on changes in risk- category and the functional status of patients, in response to prior therapies, changes in patient preferences, and other factors. Resistance to chemotherapy is a serious obstacle to the successful treatment of overall malignancies, including AML and MDS. The failure of therapeutic treatment may be due to the development of multidrug resistance (MDR) phenotype. MDR represents the induction of large-scale defensive mechanisms from which the upregulation of membrane transporters (like P-glycoprotein – P-gp) effluxing chemotherapeutic drugs from tumor cells represents the most observed molecular causality. Other mechanisms of MDR include drug metabolism, alterations in drug-induced apoptosis, epigenetic changes, epithelial-mesenchymal transition, alteration in drug targets structures, and acceleration of DNA repair. The present contribution represents a state-of-the-art review of available knowledge about this issue.
- 650 _2
- $a myelodysplastické syndromy $x terapie $7 D009190
- 650 _2
- $a akutní myeloidní leukemie $x terapie $7 D015470
- 650 _2
- $a léková rezistence $7 D004351
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a lidé $7 D006801
- 700 1_
- $a Imrichová, Denisa $7 _AN095563 $u Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences, Bratislava, Slovakia
- 700 1_
- $a Cocuľová, Martina $7 _AN095564 $u Institute of Biochemistry and Microbiology, Faculty of Chemical and Food Technology, Slovak University of Technology, Bratislava, Slovakia
- 700 1_
- $a Zelina, Marián $7 _AN074734 $u Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences, Bratislava, Slovakia
- 700 1_
- $a Budáková, Lucie $7 xx0128323 $u Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences, Bratislava, Slovakia
- 700 1_
- $a Kavcová, Helena $7 _AN095565 $u Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences, Bratislava, Slovakia
- 700 1_
- $a Šereš, Mário $7 xx0247784 $u Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences, Bratislava, Slovakia
- 700 1_
- $a Boháčová, Viera $7 xx0195027 $u Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences, Bratislava, Slovakia
- 700 1_
- $a Lakatoš, Boris $7 _AN095567 $u Institute of Biochemistry and Microbiology, Faculty of Chemical and Food Technology, Slovak University of Technology, Bratislava, Slovakia
- 700 1_
- $a Sulová, Zdena, $d 1957- $7 xx0144814 $u Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences, Bratislava, Slovakia
- 700 1_
- $a Breier, Albert, $d 1957- $7 xx0194103 $u Institute of Biochemistry and Microbiology, Faculty of Chemical and Food Technology, Slovak University of Technology, Bratislava, Slovakia; Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences, Bratislava, Slovakia
- 773 0_
- $t Myelodysplastic syndromes $z 978-953-51-2586-0 $g (2016), s. 181-200 $w MED00194796
- 856 41
- $u https://cdn.intechopen.com/pdfs-wm/50888.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $y 4 $z 0
- 990 __
- $a 20180329091135 $b ABA008
- 991 __
- $a 20180403122944 $b ABA008
- 999 __
- $a ok $b bmc $g 1286177 $s 1006325
- BAS __
- $a 8
- BMC __
- $a 2016 $d 181-200 $m Myelodysplastic syndromes $x MED00194796 $z 978-953-51-2586-0
- LZP __
- $a NLK 2018-01/jt
